Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why? (Q37873379)

24 August 2017

1 reference

title

Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why? (English)

1 reference

24 August 2017

0 references

0 references

Arcadi Cipponi

1

1 reference

24 August 2017

Grégoire Wieers

series ordinal

2

1 reference

24 August 2017

Nicolas van Baren

series ordinal

3

1 reference

24 August 2017

Pierre G Coulie

series ordinal

4

1 reference

24 August 2017

publication date

7 May 2011

1 reference

Cancer Immunology, Immunotherapy

24 August 2017

published in

1 reference

24 August 2017

volume

60

1 reference

24 August 2017

issue

8

1 reference

24 August 2017

page(s)

1153-1160

1 reference

Cancer-related inflammation

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Progress in the development of immunotherapy for the treatment of patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Comparison of prognostic factors for survival and recurrence in malignant melanoma of the skin, clinical Stage I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Model predicting survival in stage I melanoma based on tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Effector memory T cells, early metastasis, and survival in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Direct evidence to support the immunosurveillance concept in a human regressive melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillanc

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Heterogeneity of T-cell clones infiltrating primary malignant melanomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Heterogeneity in expression of human leukocyte antigens and melanoma-associated antigens in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

MHC class I antigens, immune surveillance, and tumor immune escape.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Tumor-induced disruption of proximal TCR-mediated signal transduction in tumor-infiltrating CD8+ lymphocytes inactivates antitumor effector phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Suppression of proximal T cell receptor signaling and lytic function in CD8+ tumor-infiltrating T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Immune resistance orchestrated by the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Human T cell responses against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I–II AJCC skin melanoma: Outcome analysis from a single-institution prospectively collected database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1026-2

10.1007/S00262-011-1026-2

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference